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Anti-host cytotoxic Τ cells of bone marrow transplant recipients with
or without graft-versus-host disease are equally sensitive to
cyclosporin Α
LM Liem, JT van Noort and Ε Goulmy
Department of Immunohematology and Blood Bank Leiden Univenity Hospital The Netherlands
Summary:
It is generally accepted that cytotoxic Τ cells (CTLs)
play an important role in the pathogenesis of graft-ver-
sus-host disease (GVHD). Nonetheless, anti-host CTLs
can be observed in the peripheral blood of patients both
with and without clinical signs of GVHD following HLA
genotypically identical bone marrow transplantation.
Thus we questioned whether a qualitative difference,
such as a differential in vitro sensitivity to cyclosporin Α
(CsA), may exist between the anti-host CTLs, generated
from these groups of patients post-bone marrow trans-
plantation (BMT). We analyzed anti-host CTL precur-
sors (CTLp) of patients without clinical signs of GVHD,
of patients suffering from acute GVHD (grade II-IV)
and of patients suffering from acute GVHD followed
by chronic GVHD for their in vitro sensitivity to the
inhibitory effects of CsA. The results obtained in a total
of 20 patients revealed anti-host CTLp frequencies
(CTLpf) post-BMT in all three groups of patients and
addition of CsA in the tests resulted in approximately
60% Inhibition of the CTLpf independent of the GVHD
Status of the patients. Thus, in view of the in vitro CsA
sensitivity, no difference exists between the anti-host
CTLs in patients with or without GVHD.
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The lesults of clinical bone manow transplantation (BMT)
show that the selection of MHC identical siblmg bone mar
iow donors does not guarantee avoidance of giaft-versus
host disease (GVHD) graft failuie or disease-free survival '
It is beheved that dispanties of mmor histocompatibihty
antigens (mHag) bt-tween donoi and lecipient constitute a
potential nsk factoi for GVHD oi graft failure ^ Ovei the
last few yeais, f vidence has accumulated that mHag spec
lfic helper Τ cells (Th) could be rele ^ant to the pathogenesis
of GVHD In vitro studies reporting on host directed Th
cells have been descnbed in patients with GVHD s~1 Van
Eis et alk »eported on the long-teim kinetics of Th cells in
tesponse to host mHag in 16 patients and dcmonstrated that
sigmficant Th cell activity in vitro correlated with clinical
acute GVHD Studies on the phenotype and function of Τ
lymphocytes lnfiltrating the skin dunng GVHD following
allogeneic HLA-identical BMT revealed CD8 cells,9 but
predominantly CD4 cells 1 0 ' ' Most recent observations
support the notion that mHag specific, IL-2 producmg Th
cells are hkely to play a role m the pathogenesis of acute
G V H D 1 2 n
Several reports demonstrated the presence of anti host
mHag-specific cytotoxic Τ cells (CTLs) in patients
suffering from GVHD aftei HLA genotypically identical
BMT I 4 19 However, the lole of anti-host CTLs in the
development of GVHD is still controversial In our eaiher
studies, we demonstiated the presence of anti host mHag-
specific CTLs in the blood of patients undergoing GVHD
Although patients with chronic GVHD tended to develop
highei and more persistent levcls of anti-host CTL activity
than thosc without GVHD, this finding was not statistically
sigmficant16 Subsequent analyses at the quantitative level,
le determination of the anti-host specific CTL precursoi fre-
quency (CTLpf) levealed high frequencies of mHag spec-
ific CTLs eaily after BMT irrespective of the GVHD Status
of the patient 9° In vitro data in suppoit of a role of CTLs
in GVHD in man were provided by Kaminski et aVx The
fiequency of recipient-reactive CTLp piesent in donor PBL
befoie BMT was found to predict the seventy of GVHD
after BMT Howevei, the donoi-iecipient pairs in the latter
study weie umelated HLA-matched, MLC-nonreactive
individuals
These results uiged us to le-analyze the role of the anti
host CTLs in the development ot GVHD Eaiher studies
in kidney grafting showed that the in vitro resistance of
lecipients' lymphocytes foi the immunosuppressive drug
cyclosponn Α (CsA) was coirelated with a higher late of
giaft loss " We theiefoic set out to investigate whethei we
could find diffeiences in the in vitro CsA sensitivity of anti
host CTLs in patients with and without GVHD Here we
present the lesults obtained in 20 lecipients analyzed at the
anti-host CTLp level at different times after HLA geno
typically identical BMT
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74 Material and methods
Patients
Twenty HLA genotypically identical donor-recipient pairs
are included in this study. All except one patient (UPN
11) receivcd non Τ cell-depleted bone marrow. AU patients
received cyclophosphamide (60 mg/kg/day χ 2) and total
body irradiation (8 Gy) as pretransplant conditioning regi-
men, except UPN 9 who received 4 x 50 ng/kg cyclophos-
phamide, 5 x 1 mg/kg busulphan and five treatments with
Campath and UPN 11 who received 4 χ 150 mg cyclophos-
phamide, 4 χ 75 mg busulphan and five treatments with
Campath. Methotrexate (MTX) and/or CsA (and in one
case methylprednisone) was given as GVHD prophylaxis.
The relevant clinical information is summarized in Table
1. Patients are divided into groups according to their
GVHD status. The 'no GVHD' group consists of patients
without GVHD or with acute GVHD grade I (n = 7). The
'acute GVHD' group consists of patients with acute GVHD
grade II-IV (n = 7) and the 'chronic GVHD' group consists
of patients who suffered from chronic GVHD which was
prcceded by acute GVHD grade I or more (n - 6).
Blood samples
Heparinized blood samples were taken from the recipients
before and at regulär intervals after BMT and from their
bone marrow donors. Peripheral blood leukocytes (PBL)
were isolated by Ficoll-amidotrizoate density gradient cen-
trifugation and cryopreserved in liquid nitrogen. Α total of
61 samples post-BMT was used for analysis.
Cyclosporin Α
CsA was a kind gift from Sandoz, Basel, Switzerland. It
was dissolved at 1 mg/ml in ethanol. CsA was used in a
final dilution of 50 ng/ml culture medium, corresponding
to therapeutical levels, and was present during the whole
culture period.
Limiting dilution analysis
Responder cells (RC) were PBL from the donor and PBL
from the recipient at several dates after BMT. Seven con-
centrations of RC (ränge: 40000-625 cells per well) were
set up in round-bottom microtiter plates in the presence of
5000 irradiated (5 Gy) stimulator cells (SC) in a total vol-
ume of 200 μΐ RPMI 1640 medium supplemented with
10% pooled human serum and 20 U/ml rIL-2. Stimulator
cells were Epstein-Barr virus transformed Β cell lines
(EBV-BLCL) of the recipient before BMT or of an unre-
lated individual. EBV-BLCL were used as SC because of
the limited number of PBL of the recipients before BMT.20
Target cells were PBL stimulated with 1 % PHA for 3 days
and restimulaled with irradiated (3 Gy) feeder cells once
every week for 1 or 2 weeks. In this way a Τ cell line of
each target was made to ensure sufficient target cells. Of
each dilution, 18 wclls were set up in two senes: one series
with and one without CsA in the culture medium. All
responder-stimulator combinations of each patient were set
up simultaneously and tested on the same day in the same
experiment. After 5 days, 100 μ.1 culture medium contain-
ing 20 U/ml rIL-2 was refreshed. At day 7, each well was
tested for cytotoxicity against 5000 Europium-labelled23
Table 1 Relevant clinical data of the patients included in this study
UPN
2
3
4
5
18
16
23
6
20
7
8
9
17
22
10
11
12
13
14
15
Sex (P/D)
F/M
M/M
M/F
M/F
F/F
F/M
F/F
F/M
M/F
F/F
F/M
M/M
M/M
M/M
M/M
M/F
F/M
F/M
F/M
F/F
AML-M4
AML-Ml
AML-M2
AML-M3
ALL
AML-M4
ALL
AML-M4
AA
AML-M2
AML-M3
NHL/AML-M4
AML-Ml
AML-M4
AML-M2
CML
CML
AML-M2
AML-M4
AML-M4
Conditioning
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBi
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBI
CBE
Cy/TBI
Cy/TBI
Cy/TBI
CBC
Cy/TBI
Cy/TBI
Cy/TBI
Cy/TBI
Piophylüxis
MTX
MTX
MTX
MTX
MTX
CsA
CsA + MTX
CsA
MTX
CsA
MTX
CsA
CsA
MTX
MP
CsA
CsA
MTX
MTX
CsA
aGVHD {day)"
0
0
0
0
0
I (+42)
K+8)
II (+14)
II (+34)
II—III (fl2)
III (+54)
III (+17)
III (+11)
III (+47)
II (+27)
II (+37)
I—II (+11)
IV (+28)
II (+35)
I (+17)
cGVHD
0
0
0
0
0
0
0
0
0
0
0
0
0
0
severe
severe
mild
seveie
mild
severe
Survival (day.\)h
ahve
ahve
ahve
ahve
ahve
ahve
ahve
+175
+147
ahve
ahve
+107
+137
+158
ahve
+243
ahve
+397
alive
ahve
UPN = uniquc patient number, P/D = sex oi patient (P) and donor (D), SAA = severe aplastic anemia, ALL = acute lymphoblastic leukemia, AML =
acute mycloid leukemia with FAB classification, CML = chronic myeloid leukemia (chronic phase); NHL = non-Hodgkin lymphoma Cy/TBI = cyclophos-
phamide and total body Irradiation, CBC = cyclophosphamide, busulphan, Campath and Τ cell depletion, CBE = cyclophosphamide, busulphan and
Campath, CsA = cyclosporin A, MTX = methotrexate, MP = methylprednisone.
aDay of onset of acute GVHD
bSuivival follow~up of paüeiHs süli ahve is 3=1 ycar post-BMT
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target cells in the cell-mediated lympholysis (CML) test
EBV BLCL were nevei used as target cells to exclude the
contnbution of EBV antigen specific CTLp to the value
measured20 24 Wells were considered positive, when fluor
escence exceeded the mean spontaneous lelease (18 wells
containing no RC) plus 3 Standard deviations (s d ) 21
Statistical analysis
Frequencies of responding CTLp, their 95% confidence
mteival and the goodness of fit were calculated using the
Jackknifed maximum likehhood method25 The Mann-
Whitney U test was used to compare the effect of CsA in
the different patient groups
Results
Twenty patients were divided into thiee gioups aecording
to then GVHD Status PBLs were isolated before and at
different dates after HLA genotypically identical BMT and
used to determine host directed CTLpt of each patient in
hmiting dilution assays, with and without the addition of
CsA to the test
Figuie 1 demonstrates three repiesentative expenments
of the CTLpf with or without the addition of CsA measuied
in a patient without GVHD (UPN 4), in a patient with acute
GVHD (UPN 8) and in a patient with acute GVHD fol-
lowed by chrome GVHD (UPN 13) Independent of the
oeeunence of GVHD, the post-BMT anti-host CTLpf
inercase from day 30 post BMT onwards, reach maximum
levels around day 100 and decrease gradually thereafter
Figure 1 IS also representative for our gcncral findmg that
the CTLp are equally susceptible foi the addition of CsA in
the eulture medium in the three groups of patients studied
Figuie 2 demonstrates 61 anti host CTLpf measured,
with and without CsA in vitro, in a total of 20 patients
post BMT The mean CTLpf of the 'no GVHD' patients
without addition of CsA in the medium is 17 8/106 PBL
(ränge 0-62/106 PBL) The addition of CsA leads to strong
Inhibition of most CTLpf (% Inhibition = 56%, Table 2),
although two out of seven patients still show a significant
CTLpf in the presence of CsA (>25/106 PBL) The mean
CTLpf in the piesence of CsA is 7 8/106 PBL (lange 0-
68/106 PBL) Statistical analysis shows a significant Inhi-
bition of the CTLr/f by CsA piesent in the medium (P =
0 0138, Table 2)
In the 'acute GVHD' gioup the mean CTLpf without
CsA present is 96/106 PBL (lange 0-992/106 PBL) The
CTLpf found m the picscncc of CsA are mostly very low
or absent (rrcan CTLpf = 31 4/106 PBL, ränge 0-403/10f
PBL), but ilso here two out of seven patients still show a
significant CTLpf Thiee out of seven 'acute GVHD' pati
ents have a higher CTLpl (M00/106 PBL) than 'no
GVHD' patients at at Ieast one time point post-BMT,
whercas the others do not diffei in then CTLpf Statistical
analysis shows that CsA in the medium causes a significant
Inhibition of the CTLpf (% Inhibition = 67%, Ρ = 0 0187)
The mean CTLpf of chrome GVHD patients is the high
est of the thiee groups (mean = 161/106 PBL, ränge Ο-
Ι 801/10f1 PBL) Thiee out ol six 'chrome GVHD' patients
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Figure 1 Kmetics of CTLpf after BMT of a patient without GVHD
(UPN 4) ot a patient sutfermg from acute GVHD (UPN 8) and of τ
patient suftenng from acute GVHD followed by chrome GVHD (UPN
13) GVHD Status indicated with -in astensk is lepiesented as giade I (1
= very mild) to IV (4 = seveie) CTLpf without CsA ate represented with
a stiaight linc CTLpt in the piesence of CsA aie lepiesentcd with a
dashed line
have highei CTLpf than 'no GVHD patients at at Ieast one
time point post BMT Α majonty ol chrome GVHD pati-
ents (four out of six) has also a lelatively high CTLpf in
the piesence of CsA The mean CTLpf in the presence of
CsA is 69 5/106 PBL (lange 0-891/106 PBL) The Mann-
Whitney U test for companson shows that CTLpf in the
absence 01 piesence of CsA aie not significantly diffeicnt
(% Inhibition = 57%, Ρ = 0 1066) Summaii7ing, our lesults
suggest that CsA leads to a significant deciease in CTLpf
in patients without GVHD and patients with acute GVHD,
but not in patients with chrome GVHD Α large vanation
is found in post-BMT CTLpf between patients with GVHD
The data are summaiized m Table 2 The mean CTLpf
obseived in the thiee groups of patients without oi with
CsA added in the eulture medium are indicated and is the
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Figure 2 Each hnc represents the CTLpf with and without CsA of onc sample post BMT All samples of onc patient arc represenled with thc same
Ime and symbol
Table 2 CsA sensitivity ol C FLpf in difierent patient groups
Paticnts
No GVHD η = 7
Acute GVHD η = 1
Chiomc GVHD η = 6
No samples
20
23
18
CsA added
No
Yes
No
Yes
No
Yes
Mean CTlpj (/10()
178
79
96 0
31 4
161 0
69 5
sd
184
16 7
228 2
89 8
421 2
208 6
% Inhibition
56
67
57
Mann-Whitney
/> = 0 0Π8
Ρ = 00187
^ = 0 1066
Patients were divided into three groups aotording to GVHD Status Twenty post BMT samples of seven patients without GVHD or acute GVHD giade
I 23 samples of seven patients with acute GVHD II—IV and 18 samples of patienls with chrome GVHD following acute GVHD grade I or more weie
tested The percentage Inhibition = (1 (mean CILpf with CsA/mcm CTLpf without CsA)) χ 100% s d = Standard deviation Ρ values companng CTI pf
without CsA with CTLpf with CsA are calculated using the Mann-Whitney U test
highest in the 'chrome GVHD' group The effect of CsA
presented as the percentage Inhibition of the mean CTLpf
IS, although comparable, the strongest in the acute
GVHD group
Discussion
More than a decade ago, lt was estabhshed by in vitro
expenments that CsA mediates suppression of pnmary
CTL responses 2 6 Studies by Hess et αΓΊ subsequently dem
onstrated the resistance to CsA of pnmed CTL Similarly,
on the CTLp level, the frequency of CTL grown out of
pnmed mixed lymphocyte eulture cells is not influenced by
CsA Yet CsA has a profound mfluence on thc pnmary
activation of alloreactive CTLp induced in MLC bulk cul-
tures 2 8 2 9 Vanability in CsA resistance seems to exist at
the mdividual as well as at the clonal level TO The climcal
significance of the differential in vitro CsA susceptibihty
is leflected in studies wherein the in vitro CsA resistance
appeared to correlate with a high rate of kidney graft loss
due to acute rejeetton22 Muluk et aP' demonstrated that the
CD4+ Th cells reactive with alloantigen-denved peptides
presented on self-antigen presenting cells (indirect
pathway) are mainly responsiblc for kidney graft rejection,
this population of cells appeared most sensitive to CsA as
well1 2 Some patients awaiting kidney transplant form anti-
bodies agamst HLA antigens due to previous transfusions,
pregnancies or failed transplants In these highly sensitized
paticnts it is notable that CTL against HLA antigens toward
which the patient has developed antibodics (not acceptable
mismatches) were lesistant to CsA in vitio whereas CTL
Measurement of CsA sensitivity of CTL post-BMT
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agdinst HLA antigens toward which no antibodies were
present (acceptable mismatches) were sensitive to CsA in
vitro " Additional observations supporting the notion that
a decreased in vitro CsA sensitivity of organ donor reactive
CTLp is correlated with a higher nsk of graft rejection was
substantiated by studies in corneal grafting34 and heart
transplantation v
These results prompted us to investigate whether a
decrease m CsA sensitivity of CTLp would correlate with
an mcreased nsk for GVHD after HLA genotypically ldent-
lcal BMT To lest this assumption, we analyzed the in vitro
CsA sensitivity of the anti host CTLpf in a 7-day limitmg
dilution assay Our results differ from those descnbed for
organ transplantation, but are in lme with previous results
wheie no differences in mhibitory effects of IL-2 pro-
duction mediated by CsA were observed between patients
with or without acute GVHD 1 6 We observed no clear dif-
ference between patients suffenng from either acute or
chronic GVHD and patients with no GVHD Neither was
there a difference in CsA sensitivity of patients who used
MTX or CsA as GVHD prophylaxis, nor did we notice an
mfiuence of dispanties for the known minor histocompat-
ibihty antigens between bone marrow donor and lecipient 4
CsA is able to mhibil the CTLpf in vitro in the thrce groups
of patients, although an mterindividual vanabihty in the in
vitro CsA sensitivity was noted, a phenomenon descnbed
before by o thers T O 1 7 The appaient tendency of enhanced
resistance to CsA of the 'chronic GVHD' gioup (Mann-
Whitney U test, Ρ = 0 1066) must therefore be interpieted
with care in view of the mterindividual CTLpf and CsA
vanabihty previously mentioned
Yet the increment of CsA-resistant CTL observed in the
chronic GVHD patients may be mdicative of a higher nsk
of devclopment ol chronic GVHD The hmited patients'
matenal diü not allow us to evaluate whether higher con-
centrations of CsA would break this lesistance The pres-
ence of this relatively resistant anti-host CTL population
may also reflect the composiüon of a diffeient CTL popu-
lation as opposed to acute GVHD, related to the chronic
form of GVHD
In chronic GVHD the conlmuous Stimulation of GVHD
related Τ cells might give nse to an mciease m CD45R0'~
memory Τ cells Recent data suggests that CD45R01" Τ cells
are less susceptible to the mlv'oitoiy effects of CsA than
CD45RA1 naive Τ cel l s 1 8 An inercase in CsA resistant
CD45R0^ Τ cells will then decrease the overall CsA sensi-
tivity of the total PBL pool
The aim of this study was to find a raison d'etre for the
anti-host CTL observed in patients without any chmcal
signs of GVHD Heieto we investigated whether there may
exist a differential sus^eptibihty for CsA between anti host
CTL observed in patients with or without GVHD Our data
show however that in an HLA genotypically identical Situ-
ation no corrclation is found post-BMT between the in vitto
sensitivity for CsA of anti-host CTLs and the oecurrence
of chmcal GVHD
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